|
RGP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.90520990282084E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.67129995901172E-09 |
| Normal-vs-Stage2 |
1.71928000000099E-05 |
| Normal-vs-Stage3 |
5.50830003831493E-09 |
| Normal-vs-Stage4 |
5.83039999613177E-08 |
| Stage1-vs-Stage2 |
8.597400E-01 |
| Stage1-vs-Stage3 |
1.969840E-01 |
| Stage1-vs-Stage4 |
3.245200E-01 |
| Stage2-vs-Stage3 |
5.014800E-01 |
| Stage2-vs-Stage4 |
5.935000E-01 |
| Stage3-vs-Stage4 |
9.532400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.037899766132E-10 |
| Normal-vs-AfricanAmerican |
1.095240E-03 |
| Normal-vs-Asian |
9.13840000005273E-07 |
| Caucasian-vs-AfricanAmerican |
5.403200E-01 |
| Caucasian-vs-Asian |
6.961200E-01 |
| AfricanAmerican-vs-Asian |
4.087200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.03590033720502E-10 |
| Normal-vs-Female |
1.27110000303077E-09 |
| Male-vs-Female |
7.341300E-03 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.02539999719187E-08 |
| Normal-vs-Age(41-60Yrs) |
5.57279999924276E-10 |
| Normal-vs-Age(61-80Yrs) |
4.76950035022128E-10 |
| Normal-vs-Age(81-100Yrs) |
1.719610E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.346600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.032800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.383000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.322600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.229400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.849200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.326200E-01 |
| Classical-VS-Follicular |
1.414990E-01 |
| Classical-VS-Other |
4.323700E-02 |
| Classical-VS-Normal |
7.34949989755762E-10 |
| Tall-VS-Follicular |
9.315000E-01 |
| Tall-VS-Other |
1.026240E-01 |
| Tall-VS-Normal |
1.88899999975511E-07 |
| Follicular-VS-Other |
2.251200E-01 |
| Follicular-VS-Normal |
4.51999999651065E-08 |
| Other-VS-Normal |
2.235300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.82610038201858E-10 |
| Normal-vs-N1 |
1.28309999958276E-07 |
| N0-vs-N1 |
4.173800E-01 |
|
|
